Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Targeted radiation before breast cancer surgery shows promise in small study

NCT ID NCT02186470

First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 36 times

Summary

This pilot study tested whether giving a high dose of targeted radiation (APBI) before surgery is feasible for older patients with early-stage, hormone-positive breast cancer. Twenty-two patients received the radiation followed by a lumpectomy. The goal was to see if this approach could shrink the tumor and reduce the amount of healthy tissue removed. The study focused on whether the treatment plan was reproducible and safe in the short term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IA BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

accelerated partial breast irradiation (APBI)

What this could lead to

If successful, this approach could allow smaller surgeries and less damage to healthy breast tissue for certain breast cancer patients.

What could go wrong

This is a very small, early feasibility study with only 22 participants. It does not prove that this approach is better than standard care, and long-term outcomes are not yet known.

Conditions

The condition(s) this trial relates to.

breast ductal adenocarcinoma breast mucinous carcinoma breast neoplasm breast papillary carcinoma estrogen-receptor positive breast cancer invasive ductal breast carcinoma progesterone-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.